Gelmetix

Gelmetix

Injectable polymer gel for non-surgical chronic pain treatment.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor investor

€0.0

round

£5.0m

Series C
Total Funding000k
Notes (0)
More about Gelmetix
Made with AI
Edit

Gelmetix is a UK-based medical device company developing non-surgical alternatives for chronic pain associated with osteoarthritis and degenerative disc disease. Spun out of the University of Manchester in 2012, the company was founded based on over two decades of research by Professor Tony Freemont and Professor Brian Saunders. Their work led to a patented polymer gel technology that forms injectable, durable, load-bearing gels designed to mimic the body's natural joint lubricants.

The company's lead product, DXM, is a minimally invasive, injectable hydrogel for treating chronic lower back pain caused by degenerative disc disease. Delivered in a single injection, DXM works by supplementing and rehydrating the nucleus pulposus—the core of the intervertebral disc—to restore its function, relieve pain, and potentially slow the degenerative process. This approach is positioned as a treatment option between conservative pain management, like opiate-based medication, and major surgery. The company has received approval from the French regulator (ANSM) to commence first-in-human trials.

Gelmetix's business model focuses on developing and commercializing its portfolio of biomaterial medical devices. The company has secured significant funding through multiple rounds, including a £1.2 million Series B in 2018 and a £5 million Series C in 2021, to advance its clinical trials and prepare for commercial launch. Beyond back pain, Gelmetix is developing its technology platform for other applications, including treating osteoarthritis in small joints (SXM product) and as a carrier for regenerative agents like stem cells.

Keywords: chronic lower back pain, injectable hydrogel, degenerative disc disease, nucleus pulposus augmentation, medical device, non-surgical treatment, biomaterials, osteoarthritis, polymer technology, spine degeneration, minimally invasive procedure, orthopaedics, pain management, disc rehydration, intervertebral disc, clinical trials, medtech, load-bearing gel, joint lubrication, cartilage repair

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo